Navigation Links
Cempra, Inc. to Report First Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on May 10, 2012
Date:5/3/2012

CHAPEL HILL, N.C., May 3, 2012 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP) today announced that it will report first quarter 2012 financial results and provide a business update after the close of U.S. financial markets on May 10, 2012. Prabhavathi Fernandes, Ph.D., president and chief executive officer of Cempra will host a conference call and webcast at 4:30 p.m. EDT, May 10, 2012.

The conference call may be accessed by dialing 877-377-7553 for domestic callers and 253-237-1151 for international callers. Please specify to the operator that you would like to join the "Cempra, Inc., First Quarter 2012 Financial Results Call, conference ID#: 76657626." The conference call will be webcast live under the investor relations section of Cempra's website at www.cempra.com, and will be archived there for 30 days following the call. Please visit Cempra's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Cempra, Inc.
Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates have both completed oral Phase 2 clinical trials and seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.

Investor Contacts:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
Robert.flamm@russopartnersllc.com

Andreas Marathovouniotis
Russo Partners, LLC
(212) 845-4235
Andreas.marathis@russopartnersllc.com

Media Contact:
Elliot Fox                                                                    
Russo Partners, LLC                                                             
(212) 845-4253                                                                      
Elliot.fox@russopartnersllc.com

           


'/>"/>
SOURCE Cempra Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cempra, Inc. to Present at the BioCentury Future Leaders Conference
2. Cempra, Inc. to Present at the Cowen and Company 32nd Annual Health Care Conference
3. Cempra, Inc. Announces Exercise in Full of Underwriters Option to Purchase Additional Shares
4. Cempra, Inc. Announces Pricing of Its Initial Public Offering of Common Stock
5. GP Strategies Reports Strong First Quarter 2012 EPS of $0.23
6. ResearchMoz: Telemedicine Monitoring Market Shares, Strategies, and Forecasts, Worldwide, 2012 to 2018 - Market Research Report
7. Cardinal Health Reports Third-Quarter Results
8. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 First Quarter Results
9. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
10. Neurocrine Biosciences Reports First Quarter 2012 Results
11. ResearchMoz: The World Anesthesia Drug Market (General, Local, Adjunctive) - Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... 2017  IRIDEX Corporation (Nasdaq: IRIX ) ... the first quarter 2017 after the close of trading ... will host a corresponding conference call beginning at 2:30 ... interested in listening to the conference call may do ... (703) 326-3030 for international callers, using conference ID: 92158987.  ...
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
(Date:4/19/2017)... PUNE, India , April 19, 2017 ... Type and Application, Forecast to 2022 report has covered and ... provides statistics and information on market size, shares and growth ... with major drivers, challenges and opportunities in the global market. ... Browse 152 Tables and ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... The National Campaign to Prevent Teen ... to Contraception for Women Servicemembers and Dependents Act of 2017. The bill, introduced ... to ensure that all members of the Armed Forces receive high quality education ...
(Date:4/28/2017)... ... April 28, 2017 , ... Horizon Blue Cross Blue Shield of ... rating of “A” and its outlook as “stable.” At the same time, the ratings ... fallen in recent years, dip below “capital adequacy” thresholds required for its strong rating. ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The ... board members and officers for 2017-2018. The annual board election process has been in ... a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... ... or hERG liability could substantially improve drug safety and minimize the cost of ... for validating ion channel inhibition using cell lines and for cardiac toxicity using ...
(Date:4/28/2017)... , ... April 28, 2017 , ... ... for the North East region. Côté has 20+ years of experience within the ... Phytomer, Côté worked with an array of high-end cosmetic brands, retail brands and ...
Breaking Medicine News(10 mins):